| Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Consensus Recommendations for Severe Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Modified Delphi panel consensus recommendations for management of severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
